R1 Therapeutics announces commencement of global Phase 2b trial of AP306 for hyperphosphatemia in patients on dialysis
- AP306 is a first-in-class pan phosphate transporter inhibitor in development as a monotherapy for hyperphosphatemia, a near-universal and serious complication in chronic kidney disease patients
- Study underway with first patient randomized in the global Phase 2b trial of AP306 conducted in partnership with Alebund in the US and China
- Study builds on positive Phase 2a data and is designed to evaluate AP306’s activity and tolerability across a range of doses to guide Phase 3 development
Redwood City, California – 21 July 2026 – R1 Therapeutics, Inc (“R1”), a clinical-stage biopharmaceutical company developing first-in-class therapies for patients with kidney disease, today announced that the first patient has been randomized in its global Phase 2b trial of AP306, a first-in-class pan phosphate transporter inhibitor in development as a monotherapy for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.
